News

We are pleased to announce that Redbiotec has been labeled "High Potential SME" by the Swiss Economic Forum (SEF) through a certified process. This is a further proof for Redbiotec's high value business.

Redbiotec AG has signed a new agreement with Roche Diagnostics GmbH, Germany, under which it will apply its proprietary technology platform rePAX® to produce VLPs. Roche intends to use the VLPs in an antibody discovery program in an undisclosed area.

Intercell and Redbiotec have successfully completed the proof of concept study, in which Redbiotec has applied its proprietary technology platform rePAX® in an undisclosed discovery area. Redbiotec looks forward to continue its collaboration with Intercell.

Redbiotec has been selected to present its CMV Vaccine program at the CMV 2012 Meeting in San Francisco starting October 31. Pharma companies including Novartis, Sanofi Pasteur, MedImmune, Boehringer Ingelheim with leading CMV activities will also join the meeting.

Redbiotec is pleased to announce that the project started with Merck Sharp & Dohme Corp. (NJ, USA) in October 2011, in which Redbiotec applies its proprietary technology platform rePAX® to an undisclosed discovery area, has reached a first milestone successfully and was therefore extended. We look forward to the ongoing collaboration with Merck!

Redbiotec today announced that it has closed an agreement with a listed, leading biopharmaceutical company in the field of prime-boost for cancer therapeutics to validate the approach. Christian Schaub, CEO of Redbiotec, states: “This is a major step for Redbiotec and a further proof of Redbiotec’s leadership in the development and production of complex VLPs.” Redbiotec develops VLPs for three main fields: 1) VLP vaccines, 2) VLPs for prime-boost / enhancement of cancer therapeutics and 3) VLPs, expressing GPCRs and ion channels, as targets for antibody screening.

Redbiotec today announced that it has closed a new collaboration agreement with an undisclosed company in the field of antibody generation. The goal of this collaboration is the development of new therapeutic antibodies using Redbiotec’s VLPs as targets. Under the agreement, the parties will share profit generated by the therapeutic antibodies.

The challenge experiment using Redbiotec’s tetravalent influenza VLPs was successfully finalized. Results obtained clearly show that influenza VLPs are capable of stimulating the humoral and cellular immune responses which neutralize and inhibit replication of a challenge virus. When immunized mice were challenged with a lethal dose of the parental virus, 100% of mice were protected.

Redbiotec is pleased to announce that it has entered into a collaboration with 4-Antibody, in which Redbiotec will apply its proprietary technology platform rePAX® to an undisclosed discovery area. This agreement is a further validation of the application of Redbiotec’s VLPs in antibody generation.

Prof. Polly Roy, scientific advisor to Redbiotec in the field of VLPs and antibodies for infectious diseases and cancer, has been awarded with one of India’s most prestigious academic awards.

The German Cancer Research Institute (DKFZ) and Redbiotec have extended their collaboration in the field of HPV, which started in 2009. Goal of the collaboration is the validation of chimeric VLPs, containing proteins of different serotypes on one VLP.

For the proof-of-principle, influenza A/PR/8/34 VLPs carrying four parental proteins were tested in a mouse challenge model. Preliminary results show that Redbiotec’s influenza-VLPs effectively protect the immunized mice against the parental challenge virus. Please contact us for more information to these study results.

Redbiotec has entered into a cooperation with Intercell AG (Vienna, Austria), in which Redbiotec will apply its proprietary technology platform rePAX® to an undisclosed discovery area. This agreement is an additional step in Redbiotec’s successful partnering activities during 2011.

We are proud to announce that Redbiotec has been voted 13th out of all Swiss start-up companies founded since 2006. The ranking is based on the evaluation of 100 Experts in the start-up scene. Start-up companies from all sectors (incl. IT, Cleantech and others) were evaluated. For further information, please see http://www.startup.ch.

>Redbiotec is pleased to announce that it has entered into collaboration with Merck Sharp & Dohme Corp. (NJ, USA), in which it will apply its proprietary technology platform rePAX® to an undisclosed discovery area.

Redbiotec CEO Christian Schaub has been invited to participate in the panel discussion at the Biotech Connect Day September 22 in the BioValley LifeSciences Week 2011. The BioValley Life Sciences Week is the annual networking platform for the regional Life Sciences Community in the trinational Basel area.

Redbiotec has entered into a perennial collaboration agreement with an undisclosed large pharmaceutical company. Under the contract, Redbiotec will manufacture and re-supply a relevant viral protein complex using the rePAX® technology.

Mrs Nila-Pia Raehle, formerly working for Ypsomed and Synthes, was hired in order to strengthen Redbiotec's business development. Nila has over 10 years experience in product management and deal making with pharma companies.

Redbiotec has rented 200 additional square meters of lab and office space. Till end of Q2 2011 Redbiotec will implement new cutting edge technologies into its leading rePAX® platform, including the ÄKTA avant system (GE Healthcare).

Redbiotec closes deal with Roche. Redbiotec AG, the leader in protein complexes and designer virus-like particles (VLP) enters into a collaboration with Roche, by which it will apply its proprietary technology platform [rePAX®] to an undisclosed discovery area. After having successfully worked for two leading global vaccine players in 2010, the deal with Roche is an additional highlight of a successful year for Redbiotec.

We are proud to announce that in November 1st Dr. Tiago Vicente, joined Redbiotec as purification expert. With his strong background in downstream processing Dr. Vicente will implement specific purification methods and processes for Redbiotec's new designer VLPs, particularly in the field of Herpesviruses.

Redbiotec obtains a new grant. The grant is a initiative with the Group of Prof. Wilfried Weber, University of Freiburg, to explore further applications of Redbiotec’s REPAX™ technology.

Redbiotec has launched the development of several multi-valent virus-like particles (VLPs) against the Cytomegalovirus (CMV).

Redbiotec AG ("Redbiotec" or "the Company"), the leader in protein complexes and designer virus-like particles (VLP), today announces two new appointments to its Scientific Advisory Board. Professor Polly Roy, one of the world’s leading baculovirus specialists, and Professor Rainer Fischer, an expert in molecular immunology and molecular biotechnology, bring extensive experience and knowledge in protein engineering and in VLP-based vaccine approaches.

V+ GmbH & Co Fonds 2 KG, a German Venture Capital fund invests in Redbiotec. The investment strengthens the leading position of Redbiotec in designer virus-like particles (VLPs) and protein complexes. Solidly financed, Redbiotec is applying its unique CAP ® technology for the development of additional novel vaccine and biologic candidates.

On the occasion of BioEurope 2009 in Vienna, Europe's most important Pharma and Biotech partnering conference, Redbiotec presented its proprietary and cutting-edge protein expression technologies to the international community. Important contacts were established with leading Pharma and Biotech companies. Redbiotec is now in advanced negotiations with several of these regarding the use of its technologies for vaccine development and drug discovery. Redbiotec will also be present at the follow-on conference, BioEurope Spring 2010, in Barcelona.

In Q4 2009 Redbiotec demonstrated a specific immune response of its nature-like influenza virus-like particles in mice. The particles represent an ideal vaccine candidate as they contain all major virus antigens in one virus-like particle.

Redbiotec has successfully implemented novel disposable production technologies into its leading technology platform. These technologies garantee process efficiency with high scalability.

Starting in April 2009 we increased our total space to 300 m2. Thanks to this expansion we could double our laboratory space. The operations in the new lab space were successfully started in May 2009.

We are proud to announce that in April 1st Dr. Armando Zuniga, formerly at Crucell / Berna Biotech, joined Redbiotec as Senior Scientist. With his strong background in pre-clinical development Dr. Zuniga is responsible for the veterinary business line and for the generation and validation of animal data of Redbiotec’s vaccine candidates.

On October 6 the Nobel Assembly in Sweden awarded half of the Nobel Prize in Physiology or Medicine 2008 to Harald Zur Hausen from Deutsches Krebsforschungszentrum (DKFZ).Redbiotec is developing improved vaccines against the Human Papilloma Virus using our unique expression technology for the production of complex virus-like particles.

Redbiotec recently added 3 new prominent members to our already outstanding advisory board. Among the new advisors is Dr. Reinhard Glück, president of the Swiss Biotech Association and Executive Vice President R&D, Vaccine Discovery, Crucell - Berna Biotech.

Recently, Redbiotec moved into the area of vaccine development by applying the unique expression technology to production of VLPs. To strengthen our position in this area, Dr. Sabine Wellnitz, formerly at Novartis and Roche, joined Redbiotec as a senior research scientist with a strong background in VLP production in insect cells.

Redbiotec is collaborating with ETH Zurich in testing advantages of co-expression using IkappaB kinase (IKK) as an example. Activity of several IKK complex variations will be tested.

Biopharmaceuticals - i.e. protein based drugs - are one of the fastet growing type of drugs and expertise on the industrial production will be increasingly sought off. Thus Redbiotec started a collaboration with the department of Prof. Dr. Thierry Voléry from the University of St. Gallen in the form of a master thesis.In the next 6 month to come current industrial production processes will be systematically analysed upon optimization potential through the leading baculovirus technology of redbiotec.

Redbiotec has successfully expressed difficult to produce proteins - kinases - for the german biotech company Crelux. The proteins are being used as drug targets for the discovery of pharmaceuticals.Though time was short, Redbiotec mastered the challenge of significantly increasing the yield. „Redbiotec has been the perfect partner for our challenging projects.Therefore we will tighten our collaboration in the future." Dr. Ismail Moarefi, Chief Scientific OfficerCrelux, Munich

Redbiotec is strengthening its team by hiring highly qualified people in research and development.

Rebiotec sealed its first work contract deals with an industrial customer and is actively pursuing negotiations with other potential customers in the pharma/ biotech sectors.

Redbiotec opened its new office and laboratory in Schlieren, near Zurich, alongside an established core of several successful bioech companies.

Redbiotec has received financial support through the Volkswirtschaftsstiftung.

Redbiotec has negotiated an exclusive license deal with the ETH Zürich over patented MultiBac technology and the ETH has now become a partner and shareholde of Redbiotec.

Redbiotec was incoporated as an Aktiengesellschaft. All founders of the patented MultiBac technology are shareholders of Redbiotec AG. Soon the ETH Zürich will become shareholder too.

Under the former name XpresSys the team of Redbiotec wins the second prize of the Venture 2006. This success is based on the excellent businessplan, the attractive technology and on the strong founder team. Redbiotec was superior on nearly 100 other projects.Venture 2006 is an initiative of the ETH Zurich and McKinsey & Company, Switzerland. The Swiss-wide business plan competition supports young entrepreneurs in founding a company. Venture 2006 – as did Venture 98, 2000, 2002 and 2004 – aims to put to use untapped innovation potential by encouraging young entrepreneurs to develop a business idea. A number of renowned companies from Swiss industry and commerce sponsor the competition.